Month: June 2024

1931 posts
TalentCorp Leverages Malaysian Expertise Abroad: Announces Grant for Tokyo-Based Malaysian Researchers for Conference Collaboration

TalentCorp Leverages Malaysian Expertise Abroad: Announces Grant for Tokyo-Based Malaysian Researchers for Conference Collaboration

KUALA LUMPUR, Malaysia, June 3, 2024 /PRNewswire/ — Talent Corporation Malaysia Berhad (TalentCorp),…
Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting

Results from the phase I part of JSKN003-102 was reported at this ASCO…
Inspur Group Making Its Debut at the 2024 Asia Tech x Singapore (ATxSG)

Inspur Group Making Its Debut at the 2024 Asia Tech x Singapore (ATxSG)

SINGAPORE , June 3, 2024 /PRNewswire/ — The 2024 Asia Tech x Singapore (ATxSG)…
GMM Music Announces Strategic Partnership with Tencent Music Entertainment Group and Tencent, with a Strategic Investment Valuing GMM Music at 0 Million USD

GMM Music Announces Strategic Partnership with Tencent Music Entertainment Group and Tencent, with a Strategic Investment Valuing GMM Music at $700 Million USD

BANGKOK, June 3, 2024 /PRNewswire/ — GMM Music today announced a strategic…
ATxSG2024: Sunwave Highlights Wireless and Satellite Innovations

ATxSG2024: Sunwave Highlights Wireless and Satellite Innovations

SINGAPORE, June 3, 2024 /PRNewswire/ — During ATxSG 2024 from May 29th…
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting

Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ — Innovent Biologics,…
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2024 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent")…
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University

China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University

Wistron and imedtac jointly promote leading medical products with CMUH in Malaysia…